Myasthenia Gravis Trial, Recruiting NCT07413835 Sponsor: The Affiliated Hospital of Xuzhou Medical University Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Myasthenia Gravis Trial, Recruiting

NCT07413835
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old (any gender)
  • You have been diagnosed with generalized myasthenia gravis (MG) — a condition that causes muscle weakness — and your blood tests show specific antibodies linked to this disease (AchR or MuSK antibodies)
  • Your diagnosis has been confirmed by at least one of the following: a nerve stimulation test showing a problem with how nerves and muscles communicate; a positive response to a medication test using neostigmine; or noticeable improvement in MG symptoms after taking a type of oral medication called a cholinesterase inhibitor
  • Your MG falls within a moderate-to-severe range based on a standard medical classification system (MGFA types IIa through IVb) (confirm with trial site)
  • Your daily life is meaningfully affected by MG symptoms, measured by a standard scoring tool, and your symptoms are not mainly limited to your eyes (confirm with trial site)
  • Standard treatments for MG have not worked well enough for you
  • Your overall health is expected to be stable for at least the next 12 weeks
  • Your bone marrow, blood clotting, heart, lungs, liver, and kidneys are all functioning at an adequate level

Who may not be able to join:

  • You currently have active or detectable hepatitis B, hepatitis C, HIV, CMV (a type of viral infection), or syphilis
  • You have another active infection that is not under control
  • You have previously had a major organ transplant (such as heart, lung, liver, or kidney) or a bone marrow/stem cell transplant
  • You are currently pregnant or breastfeeding
  • You have received a treatment based on mRNA-LNP technology (such as certain vaccines or experimental drugs) within the past two years (confirm with trial site)
  • You have had a serious heart condition in the past 6 months, such as heart failure, a heart attack, unstable chest pain, or certain types of abnormal heart rhythms
  • You have had a significant bleeding episode in the past 30 days, or you need to take blood-thinning medication long-term (such as warfarin or similar drugs)
  • You have received a live vaccine in the past 30 days
  • You have a serious brain or nervous system condition, such as epilepsy, stroke, dementia, Parkinson's disease, or psychosis, among others
  • You have a history of asthma or severe allergic reactions
  • Your doctor believes that participating could put you at increased risk or affect how the trial results are measured

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Guiyun Cui, The Affiliated Hospital of Xuzhou Medical University

Phone: 86-0516-85802193

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Registry
ClinicalTrials.gov
Start date
17 March 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Treatment-Emergent Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov